Edition:
United Kingdom

OncoTherapy Science Inc (4564.T)

4564.T on Tokyo Stock Exchange

124JPY
7:00am BST
Change (% chg)

¥-3 (-2.36%)
Prev Close
¥127
Open
¥127
Day's High
¥127
Day's Low
¥124
Volume
828,300
Avg. Vol
1,211,425
52-wk High
¥217
52-wk Low
¥108

Summary

Name Age Since Current Position

Kyoko Fujiya

53 2019 President, President of Subsidiary, Representative Director

Suyoun Chung

35 2019 Director of Clinical Development, Director

Takuya Tsunoda

54 2014 Director

Hiroshi Yamaji

53 2005 Director

Toyomasa Katagiri

47 2010 Independent Director

Biographies

Name Description

Kyoko Fujiya

Ms. Kyoko Fujiya was named President and Representative Director in OncoTherapy Science, Inc., as well as President and Representative Director of a subsidiary, Cancer Precision Medicine, Inc., effective January 23, 2019. Her previous titles include Executive Officer and Senior Director of Business in the Company. She used to work for GE Healthcare Japan Corporation and another company. She obtained her Bachelor's degree in English from Shibuya Institute of Foreign Languages in March 1986, and her Bachelor's degree in Management Information from SANNO UNIVERSITY in September 2003.

Suyoun Chung

Ms. Suyoun Chung was named Director of Clinical Development and Director in OncoTherapy Science, Inc. effective January 12, 2019. She was also named President and Representative Director in OncoTherapy Science, Inc. effective November 30, 2018. She joined the Company in April 2015. She previously served as Executive Officer in the Company. She used to work for National Cancer Center Research Institute and University of Chicago, the United States. She obtained her Ph.D. in Life Science from University of Tokyo in March 2011.

Takuya Tsunoda

Mr. Takuya Tsunoda has been serving as Director in OncoTherapy Science, Inc. since July 1, 2014. He is also working for another company and University of Tokyo. His previous titles include Vice President and Chief Director of Research and Development. He used to work for City of Hope National Cancer Institute, Wakayama Medical University, and another company.

Hiroshi Yamaji

Mr. Hiroshi Yamaji has been serving as Director in OncoTherapy Science, Inc. since June 2005. He is holding directorship in an affiliated company and a subsidiary. He joined the Company in February 2003. His previous titles include Director of Development and Director of Business Development. He used to work in a few companies, including Sankyo Co., Ltd., Eli Lilly Japan K.K., sanofi-aventis K.K., GlaxoSmithKline, as well as Pfizer Japan Inc.

Toyomasa Katagiri

Mr. Toyomasa Katagiri has been serving as Independent Director in OncoTherapy Science Inc since June 25, 2010. He is also working for The University of Tokushima as Professor. He used to work for The Institute of Medical Science, The University of Tokyo.

Basic Compensation

Options Compensation